Over the last ten years, the treatment options for psoriasis in China have changed quickly, thanks to rising public awareness, better diagnostic tools, and enhanced access to modern dermatological services. Educational initiatives from national dermatological groups and leading academic medical centers have played a role in reducing stigma, promoting earlier visits to healthcare professionals, and boosting diagnosis rates, which in turn has led to more patients engaging in structured treatment programs. Major urban hospitals, especially in cities like Beijing, Shanghai, and Guangzhou, have developed specialized dermatology centers that offer thorough management for psoriasis, featuring assessments of severity, ongoing monitoring, and teamwork among different specialties. As understanding of the condition has risen, both patients and doctors in China have become more open to utilizing advanced treatment options, particularly new biologics aimed at inflammatory pathways such as IL-17 and IL-23. China has also emerged as a primary center for dermatological clinical research, with international pharmaceutical companies and local biotech enterprises conducting extensive studies into new treatments for psoriasis. The nation’s large patient base and improving clinical research framework make it an attractive place for testing new therapies and developing practical evidence.

Regulatory bodies have introduced changes that speed up the approval process for clinical trials and enhance international cooperation, allowing Chinese patients to access innovative treatments more quickly than they could in the past. Hospitals engaged in research efforts frequently act as early users of novel biologics, aiding the swift integration of advanced therapies into routine practice. Training programs for physicians and updated national guidelines for treatment encourage dermatologists to implement evidence-based biologic therapies for moderate to severe cases of the disease. According to the research report, " China Psoriasis Treatment Market Overview, 2031," published by Bonafide Research, the China Psoriasis Treatment market is anticipated to grow at more than 9.74% CAGR from 2026 to 2031. China is seen as one of the quickest-growing markets for psoriasis in the Asia-Pacific area, powered by its large group of patients, developing healthcare systems, and continuous progress in pharmaceuticals. The country's substantial number of individuals with psoriasis creates a significant need for both traditional treatments and advanced biologics, leading to robust market growth. Local biotechnology firms have become important players in creating and marketing biosimilars and new biologics, which helps boost competition and provides more affordable options. Domestic companies, often working together with international pharmaceutical firms, are pushing forward research on targeted therapies and aiding the expansion of clinical trials in several treatment areas, including dermatology.

Regulatory changes initiated by China’s National Medical Products Administration NMPA have simplified the process for drug approvals, fostered new ideas, and allowed quicker access for innovative treatments in the local market. The establishment of priority review routes, the acceptance of clinical trial data, and revised intellectual property laws have rendered China a more appealing landscape for pharmaceutical investments. These changes have also sped up the authorization and use of biosimilars, which are now seen as vital resources for lowering treatment expenses and broadening access to advanced therapies for patients. Hospitals and local health systems are starting to include biosimilars in their purchasing plans to meet increasing demand while addressing financial limitations. Digital pharmacies and online health platforms signify another significant opportunity for growth. China’s robust e-commerce environment enables patients to obtain medications via authorized digital pharmacies, especially for ongoing therapies and aftercare.

China psoriasis treatment market by type is divided into plaque psoriasis, psoriatic arthritis and others. China hosts one of the largest populations of psoriasis patients, with millions affected, which makes it important to classify the disease types for effective healthcare planning and pharmaceutical approaches. Plaque psoriasis is the most common subtype, representing the bulk of diagnosed cases and leading to the majority of consultations in dermatology and treatment requests. Moderate-to-severe plaque psoriasis is managed in urban tertiary hospitals and specialized dermatology centers through established treatment protocols that encompass severity assessments, escalating therapies stepwise, and ongoing monitoring. Greater awareness of the disease and enhancements in diagnostic practices have led to earlier identification and more reliable management, especially in major cities. With increasing availability of biologics and advanced systemic treatments, numerous patients with severe plaque psoriasis are now receiving targeted therapies that enhance symptom management and improve their quality of life.

Psoriatic arthritis has become a rising concern in the realm of psoriasis treatment in China, affecting a substantial number of patients and often requiring a collaborative approach involving both dermatologists and rheumatologists. Heightened awareness among clinicians and screening initiatives have led to better early identification of joint issues, which is essential for avoiding chronic disability. Since psoriatic arthritis commonly requires biologic or advanced systemic treatments, this aspect significantly contributes to the considerable use of high-value therapies and healthcare costs. Integrated hospital clinics and clinical databases are assisting physicians in monitoring disease progression and assessing treatment effectiveness in this group. The others category encompasses rarer forms such as guttate, pustular, erythrodermic, and inverse psoriasis. While these subtypes are relatively infrequent, they can be severe and necessitate management in hospitals during acute episodes or complications.

Generalized pustular psoriasis, in particular, requires specialized attention due to its potential to be life-threatening. China psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others. The treatment landscape for psoriasis in China showcases a wide array of conventional therapies alongside a swiftly growing selection of advanced biologic options. First-line treatments for mild cases remain topical therapies, including corticosteroids, vitamin D derivatives, and traditional dermatological preparations, which are extensively utilized in both urban and rural healthcare settings. These therapies are easily accessible and cost-effective, forming a crucial part of the early management strategy. Phototherapy, especially narrowband UV-B, is frequently available in hospital dermatology services and large outpatient clinics, serving as an effective intermediate treatment for moderate cases. Systemic treatments such as methotrexate, cyclosporine, and acitretin continue to have a significant role in managing moderate to severe cases, especially in areas where access to biologic therapies is curtailed by costs or reimbursement issues.

However, biologics are now the fastest-growing sector of treatment, as Chinese dermatologists increasingly incorporate targeted therapies known for their enhanced efficacy and safety. Local biotech firms and international pharmaceutical companies are rolling out new biologics and biosimilars that target inflammatory pathways like IL-17 and IL-23. National reimbursement initiatives and regional insurance plans are slowly broadening access to these treatments, promoting their use within urban hospitals and specialized clinics. The others category comprises new treatment options like targeted oral small-molecule inhibitors, combination therapies, and traditional Chinese medicine methods that are combined with modern treatments in specific clinical scenarios. Continuous clinical trials and regulatory changes are speeding up advancements in treatment and making therapies more accessible. China’s treatment classification signifies a shift from conventional topical and systemic therapies to more sophisticated biologics and tailored treatment methods, fueled by greater healthcare investments, pharmaceutical advancements, and escalating patient demands for effective long-term disease management.China psoriasis treatment market by distribution channel is divided into hospital pharmacies, retail pharmacies and e-commerce.

The distribution system for psoriasis medications in China is significantly shaped by its hospital-focused healthcare framework, the growing retail pharmacy market, and the quickly advancing e-commerce landscape. Hospital pharmacies are the main source for delivering biologic treatments and advanced systemic drugs, especially during the start of treatment and for patients suffering from moderate to severe conditions. Tertiary hospitals and specialized dermatological facilities handle complicated cases and oversee the administration, monitoring, and reimbursement of biologics through national or local insurance plans. The processes for hospital procurement and centralized buying agreements frequently affect the choice of medications, promoting the use of affordable biosimilars and domestically made biologics. Retail pharmacies play a crucial role in distributing topical treatments, oral systemic drugs, and ongoing prescriptions. China’s vast network of community pharmacies ensures easy access to medications and contributes significantly to patient education, adherence checks, and continued treatment assistance.

As healthcare reforms encourage the splitting of prescribing and dispensing duties in various regions, retail pharmacies are becoming more pivotal in managing chronic diseases. They also act as accessible locations for over-the-counter dermatological products and supportive skincare solutions commonly used by psoriasis patients. E-commerce and online pharmacy services have become one of the fastest-expanding distribution methods, bolstered by China's sophisticated digital framework and the growing use of telemedicine. Authorized online pharmacies allow patients to submit prescriptions, order medications, and receive deliveries at home, particularly aiding those in rural or less serviced regions. Collaboration with teledermatology services enables remote consultations, follow-up evaluations, and therapy monitoring. While strict regulations govern the online sale of prescription biologics, digital pharmacy services are rapidly increasing for ongoing treatments and chronic disease management. Considered in this report* Historic Year: 2020* Base year: 2025* Estimated year: 2026* Forecast year: 2031Aspects covered in this report* Psoriasis Treatment Market with its value and forecast along with its segments* Various drivers and challenges* On-going trends and developments* Top profiled companies* Strategic recommendationBy TypePlaque PsoriasisPsoriatic ArthritisOthersBy Treatment TypeBiologics DrugsSystemic DrugsTopical DrugsPhototherapyOthersBy Distribution ChannelHospital PharmaciesRetail Pharmaciese-Commerce.